Stock Scorecard
Stock Summary for Transmedics Group Inc (TMDX) - $89.25 as of 4/26/2024 3:51:06 PM EST
Total Score
5 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for TMDX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TMDX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TMDX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for TMDX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for TMDX
Financial Details for TMDX
Company Overview |
|
---|---|
Ticker | TMDX |
Company Name | Transmedics Group Inc |
Country | USA |
Description | TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts. |
Sector Name | LIFE SCIENCES |
Industry Name | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/23/2024 |
Stock Price History |
|
Last Day Price | 89.25 |
Last Day Price Updated | 4/26/2024 3:51:06 PM EST |
Last Day Volume | 0 |
Average Daily Volume | 808,421 |
52-Week High | 99.63 |
52-Week Low | 36.42 |
Last Price to 52 Week Low | 145.06% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 46.98 |
Sector PE | 56.64 |
5-Year Average PE | -36.07 |
Free Cash Flow Ratio | 7.43 |
Industry Free Cash Flow Ratio | 17.79 |
Sector Free Cash Flow Ratio | 30.65 |
Current Ratio Most Recent Quarter | 9.30 |
Total Cash Per Share | 12.02 |
Book Value Per Share Most Recent Quarter | 4.20 |
Price to Book Ratio | 21.98 |
Industry Price to Book Ratio | 3.23 |
Sector Price to Book Ratio | 22.15 |
Price to Sales Ratio Twelve Trailing Months | 12.48 |
Industry Price to Sales Ratio Twelve Trailing Months | 2.52 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
Total Shares Outstanding | 32,851,300 |
Market Capitalization | 2,931,978,525 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 30.92% |
Reported EPS 12 Trailing Months | -0.77 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -0.77 |
Net Income Twelve Trailing Months | -25,028,000 |
Net Income Past Year | -25,028,000 |
Net Income Prior Year | -36,231,000 |
Quarterly Revenue Growth YOY | 158.70% |
5-Year Revenue Growth | 78.87% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 394,812,000 |
Total Cash Past Year | 394,812,000 |
Total Cash Prior Year | 201,182,000 |
Net Cash Position Most Recent Quarter | -111,392,000 |
Net Cash Position Past Year | -111,392,000 |
Long Term Debt Past Year | 506,204,000 |
Long Term Debt Prior Year | 58,696,000 |
Total Debt Most Recent Quarter | 506,204,000 |
Equity to Debt Ratio Past Year | 0.21 |
Equity to Debt Ratio Most Recent Quarter | 0.21 |
Total Stockholder Equity Past Year | 137,202,000 |
Total Stockholder Equity Prior Year | 187,375,000 |
Total Stockholder Equity Most Recent Quarter | 137,202,000 |
Options |
|
Put/Call Ratio | 1.53 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 2.22 |
MACD Signal | 2.26 |
20-Day Bollinger Lower Band | 70.79 |
20-Day Bollinger Middle Band | 82.32 |
20-Day Bollinger Upper Band | 93.85 |
Beta | 1.98 |
RSI | 53.42 |
50-Day SMA | 73.06 |
200-Day SMA | 43.72 |
System |
|
Modified | 4/27/2024 1:06:31 PM EST |